当前位置: X-MOL 学术Alzheimers Dement. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT)
Alzheimer's & Dementia ( IF 13.0 ) Pub Date : 2021-11-17 , DOI: 10.1002/alz.12496
Nicholas M Pajewski 1 , Fanny M Elahi 2 , Manjula Kurella Tamura 3 , Jason D Hinman 4 , Ilya M Nasrallah 5 , Joachim H Ix 6 , Lindsay M Miller 6 , Lenore J Launer 7 , Clinton B Wright 8 , Mark A Supiano 9 , Alan J Lerner 10 , Tiffany L Sudduth 11 , Anthony A Killeen 12 , Alfred K Cheung 13 , David M Reboussin 1 , Donna M Wilcock 11 , Jeff D Williamson 14
Affiliation  

Lowering blood pressure (BP) reduces the risk for cognitive impairment and the progression of cerebral white matter lesions. It is unclear whether hypertension control also influences plasma biomarkers related to Alzheimer's disease and non-disease-specific neurodegeneration.

中文翻译:


收缩压干预试验 (SPRINT) 中的血浆 β 淀粉样蛋白、神经丝轻链和总 tau 蛋白



降低血压(BP)可降低认知障碍和脑白质病变进展的风险。目前尚不清楚高血压控制是否也会影响与阿尔茨海默病和非疾病特异性神经变性相关的血浆生物标志物。
更新日期:2021-11-17
down
wechat
bug